1 / 11With the whole world is racing against time to develop a vaccine against coronavirus infection, British American Tobacco, one of the largest cigarette makers in the world, is all set to start testing their potential vaccine in humans.2 / 11The London-based maker of Lucky Strike cigarettes claimed that it has made vaccine using protein from tobacco leaves.3 / 11The tobacco maker expects a response from the US Food and Drug Administration any day now, Kingsley Wheaton, chief marketing officer, Lucky Strike cigarettes, said, according to Bloomberg.4 / 11“We’re optimistic,' Wheaton said. “It’s an important part of our strategy to try and build a better tomorrow,' he added. 5 / 11The company earlier said that its experimental COVID-19 vaccine has shown a positive immune response in pre-clinical trial.6 / 11According to the company, the method generates the vaccine faster than conventional approaches, reducing the time required from several months to about six weeks.7 / 11Tobacco makers across the globe have been jumping into the race to develop a vaccine against COVID-19 that has claimed more than 6.5 lakh lives.8 / 11Medicago Inc., a biotechnology company partly owned by rival cigarette maker Philip Morris International Inc., is also developing a plant-based vaccine that could be available in the first half of 2021, if it’s successful.9 / 11There are 24 vaccine candidates in clinical trials, though the success rate of such programs is normally 10%, the World Health Organization’s chief scientist Soumya Swaminathan said last week.10 / 11Making a coronavirus vaccine using tobacco plants stands in stark contrast to the effects of other related products on health.11 / 11